There’s that ambiguity our PRs always seem to possess:

“We are very excited to have our first patient start treatment with this additional once-a-week injection intended to improve outcome in patients with metastatic triple-negative breast cancer. We hope the results of our preclinical studies are duplicated in the human trial. Since we are evaluating each patient’s circulating tumor cells (CTC) in the blood, we hope to see some positive results very quickly,” added Dr. Pourhassan.”